TVTX Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is $0.03 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.2% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Travere Therapeutics, Inc.
Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.
Sector
Healthcare
Industry
Drug Manufacturers/Other